Insulet Corp

GOV

Company Profile

  • Business description

    Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

  • Contact

    100 Nagog Park
    ActonMA01720
    USA

    T: +1 978 600-7000

    E: [email protected]

    https://www.insulet.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    3,900

Stocks News & Analysis

stocks

Unwarranted drop in ASX share

Jittery investors misinterpret an audit for an existential crisis.
stocks

Macquarie: A return to group-wide growth

Our view on the shares after earnings.
stocks

After earnings, is Disney stock a buy, a sell, or fairly valued? -

Following the highly anticipated announcement of a new CEO, here’s what we think of Disney.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,281.8097.301.06%
CAC 408,321.496.39-0.08%
DAX 4024,962.5525.30-0.10%
Dow JONES (US)50,188.1452.270.10%
FTSE 10010,401.7147.870.46%
HKSE27,266.3883.230.31%
NASDAQ23,102.47136.20-0.59%
Nikkei 22557,650.541,286.602.28%
NZX 50 Index13,507.2860.910.45%
S&P 5006,941.8123.01-0.33%
S&P/ASX 2009,014.8098.801.11%
SSE Composite Index4,131.983.610.09%

Market Movers